HC Wainwright Projects enGene’s Q1 Earnings for 2025

Investment analysts from HC Wainwright recently provided their projections for enGene Holdings Inc. (NASDAQ:ENGN) regarding its earnings for the first quarter of 2025. In a research note published on December 23rd, analyst A. Maldonado predicted that enGene would report earnings of ($0.41) per share for this upcoming quarter. Furthermore, HC Wainwright maintains a "Buy" rating on the stock with a price target of $25.00.

For context, the current consensus estimate for enGene's earnings for the entire fiscal year 2024 stands at ($1.52) per share. Alongside the Q1 estimate, HC Wainwright also shared projections for subsequent quarters in 2025: ($0.44) for Q2, ($0.38) for Q3, and ($0.39) for Q4. Cumulatively, the firm anticipates that enGene will record earnings of ($1.61) for FY2025, ($1.57) for FY2026, ($1.33) for FY2027, ($0.38) for FY2028, and a potential profit of $0.37 for FY2029.

enGene most recently disclosed its quarterly earnings on December 19th, revealing an EPS of ($0.34). This result was slightly better than the consensus estimate of ($0.40), exceeding expectations by $0.06.

Analyst Ratings and Stock Performance

Other analysts have been evaluating enGene as well. Morgan Stanley reiterated an “overweight” rating for the stock with a target price of $40.00, according to a report published on September 11th. Meanwhile, Citizens JMP upgraded enGene to a “strong-buy” rating on November 18th. Raymond James began coverage on enGene with an “outperform” rating and set a targeted price of $23.00 on November 27th. Additionally, Oppenheimer reaffirmed an “outperform” rating with a price target of $30.00 in their September 24th report. Another firm, JMP Securities, kept its “market outperform” rating but lowered its target price to $18.00.

A total of ten analysts have rated enGene with a buy recommendation, while one has issued a strong buy rating. Data from MarketBeat suggests the stock holds an average rating of “Buy” with a consensus target price of $29.78.

Recent Stock Activity

As of Wednesday, enGene's stock opened at $6.32, reflecting a trading increase of 6.0%. The company exhibits strong liquidity metrics, illustrated by a quick ratio and current ratio both at 19.52, indicating robust short-term financial health. With a market capitalization of $279.45 million, enGene's shares currently have a P/E ratio of -10.90 and a beta of -0.78. The stock has fluctuated, with a 12-month low of $4.42 and a high of $18.40.

Institutional Investment Trends

Institutional investment in enGene has been active, with several firms recently adjusting their holdings. Wolverine Asset Management LLC invested approximately $37,000 in the third quarter. Point72 Asset Management L.P. significantly increased its stake by 1,410.3% during the same period, acquiring 663,000 shares worth around $4.38 million. Other noteworthy investments include SR One Capital Management LP, which bought shares valued at approximately $4.71 million, and Franklin Resources Inc., which raised its stake by 48.7% during the third quarter. In total, hedge funds and institutional investors own about 64.16% of enGene’s shares.

Insider Transactions

insider activity has also been notable at enGene, with major shareholder Growth Opportunities F. Forbion purchasing 41,639 shares at an average price of $5.97 each on September 27th, leading to a total investment of around $248,584.83. This transaction increased their ownership to 2,059,459 shares. Additionally, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares at an average price of $5.70, with a total value of $57,000. Over the past quarter, insiders have bought 420,965 shares, totaling approximately $2.65 million, and currently hold about 13.70% of the company’s stock.

About enGene Holdings Inc.

enGene Holdings Inc. operates as a clinical-stage biotechnology firm focused on developing genetic therapies, particularly targeting mucosal tissues and organs. Its primary product candidate is EG-70 (detalimogene voraplasmid), a non-viral immunotherapy designed to treat patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin treatment.

Earnings, Finance, Analysis